Predictive Markers and Cancer Prevention
Aberrant methylation of the adenomatous polyposis coli promoter 1A in bronchial aspirates from patients with suspected lung cancer
Article first published online: 16 MAR 2004
Copyright © 2004 Wiley-Liss, Inc.
International Journal of Cancer
Volume 110, Issue 5, pages 751–755, 10 July 2004
How to Cite
Grote, H. J., Schmiemann, V., Kiel, S., Böcking, A., Kappes, R., Gabbert, H. E. and Sarbia, M. (2004), Aberrant methylation of the adenomatous polyposis coli promoter 1A in bronchial aspirates from patients with suspected lung cancer. Int. J. Cancer, 110: 751–755. doi: 10.1002/ijc.20196
- Issue published online: 11 MAY 2004
- Article first published online: 16 MAR 2004
- Manuscript Accepted: 19 JAN 2004
- Manuscript Revised: 8 DEC 2003
- Manuscript Received: 26 SEP 2003
- lung cancer;
- real-time PCR
Promoter hypermethylation is a major mechanism for gene silencing and offers a promising starting point for developing molecular biomarkers. The purpose of our study was to determine aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A with respect to its prevalence and quantitative level in bronchial aspirates from patients with suspected lung cancer. Applying quantitative methylation-specific PCR, 155 bronchial aspirates from patients with non-small cell cancer (NSCLC) and small cell cancer (SCLC) of the lung as well as 67 bronchial aspirates from patients diagnosed for nonneoplastic lung disease were examined in a retrospective case-control study. Aberrant APC promoter 1A methylation was seen in 71% of NSCLCs, 38% of SCLCs and 42% of patients with nonneoplastic lung disease, being therefore not specific for the presence of primary lung cancer. In contrast, quantitative analysis showed a significantly higher methylation level of bronchial aspirates from NSCLC as compared to patients without neoplastic lung disease. Introducing a cutoff point that defined high level of APC hypermethylation NSCLC could be discriminated from cases without neoplastic disease with a specificity of 98.5% and a sensitivity of 39%. The data suggest that quantitative analysis of APC hypermethylation may serve as a biomarker of primary lung cancer. © 2004 Wiley-Liss, Inc.